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This paper summarizes the various eﬀects of neurotrophins in skeletal muscle and how these proteins act as potential regulators of
themaintenance, function, and regeneration of skeletal muscle ﬁbers. Increasing evidence suggests that this family of neurotrophic
factors inﬂuence not only the survival and function of innervating motoneurons but also the development and diﬀerentiation of
myoblasts and muscle ﬁbers. Muscle contractions (e.g., exercise) produce BDNF mRNA and protein in skeletal muscle, and the
BDNF seems to play a role in enhancing glucose metabolism and may act for myokine to improve various brain disorders (e.g.,
Alzheimer’s disease and major depression). In adults with neuromuscular disorders, variations in neurotrophin expression are
found, and the role of neurotrophins under such conditions is beginning to be elucidated. This paper provides a basis for a better
understanding of the role of these factors under such pathological conditions and for treatment of human neuromuscular disease.
1.Introduction
Neurotrophins are best known for their roles in regulating
neuronal survival, plasticity, growth, and death [1, 2]. As
such, they have been studied predominantly in the context
of nervous system development and function. However,
accumulating evidence suggests that neurotrophins play a
more widespread role than originally thought. Accordingly,
they are now the focus of study in numerous cell popula-
tions across multiple tissue systems. Of these populations,
skeletal muscle is of particular interest, because it acts as
an abundant source of neurotrophic support throughout
development [3, 4]. In addition, skeletal muscle expresses
several neurotrophin receptors, providing the basis for
neurotrophin signaling within the muscle compartment [5].
Indeed, neurotrophin knockout mice often exhibit distinct
defects in muscle development and function, and to date
neurotrophin- (NT-) 4/5 has been implicated in muscle
ﬁber transformation, NT-3 in muscle spindle formation, and
nerve growth factor (NGF) in dystrophic muscle pathology
[6–8]. Expression proﬁling has shown that brain-derived
neurotrophic factor (BDNF) is diﬀerentially expressed in
skeletal muscle under various physiological and pathological
conditions [4]. Several studies have demonstrated that
physicalexercisecanincreasecirculatingBDNFlevelsinboth
healthy humans [9, 10] and patients with multiple sclerosis
[11]. More recently, Matthews et al. [12] clearly showed the
production of BDNF mRNA and protein by human skeletal
muscle after 2 hours of ergometer bicycle exercise. In addi-
tion, denervation causes alterations of muscle neurotrophin
levels[3,13,14],and,inseveralanimalstudies,reducedNGF
a n dN T - 3m R N Aa sw e l la sN G Fp r o t e i nl e v e l sh a v eb e e n
observed in diabetic muscle [15–18], whereas an increase in
BDNF mRNA levels has been reported [15, 19].
Glial-cell-line-derived neurotrophic factor (GDNF) was
ﬁrst discovered in glial cells and supports dopaminergic
neurons of the central nervous system [20]. GDNF induces
sprouting and muscle ﬁber reinnervation [21]a n dm a y
be involved in the maintenance of cell body size and the
cholinergic phenotype of motoneurons [22]. Earlier studies
showed the marked expression of GDNF at neuromuscular
junction (NMJ) during early myogenesis and then negligible2 Journal of Biomedicine and Biotechnology
levels.However,severalresearchersobservedclearexpression
in normal muscles of mice, after denervation, and merosin-
deﬁcient muscular dystrophy in adult animals.
This paper focuses on the eﬀects of neurotrophins (NGF,
BDNF, NT-4/5, and GDNF) on skeletal muscle and how they
act as potential regulators of the development, maintenance,
function, and regeneration of skeletal muscle ﬁbers. In mice
carrying null mutations in the NT-3 or tropomyosin-related
kinase (Trk)C gene, numbers of proprioceptive neurons and
muscle spindles are dramatically decreased [8, 23]. Con-
versely, the embryonic overexpression of NT-3 in developing
limb or muscle increases the number of proprioceptive
neurons [24, 25]. However, the muscle morphology in these
models is poorly described. In this paper, wedid not describe
a possible role of NT-3 and the receptor (TrkC) in muscle
ﬁber; only a few studies found some role of NT-3 to muscle
morphology [26, 27].
2. Normal Distribution of Neurotrophins and
TheirReceptorsinAdultSkeletalMuscle
2.1. Neurotrophins. The level of BDNF expression in animals
fuels debate as well. Low levels were reported in developing
and postnatal avian and rodent skeletal muscle [3, 28–
32]. However, other studies including our own could not
detect any BDNF expression in developing muscle of mice
and rats [14, 33]. Indeed, neither Western blotting nor
immunohistochemistry revealed immunoreactivity in the
soleus and several fast-type muscles in Wistar rats at 2–12
weeks of age. To investigate this issue in more detail, recent
studies have applied intensiﬁed in situ hybridization (ISH)
techniques for electron microscopy to detect BDNF mRNA
in muscle and, in particular, to determine the cell types
(muscle ﬁbers, satellite cells, Schwann cells, ﬁbroblasts, and
endothelialcells)thatsynthesizeBDNF.Thesestudiessuggest
the expression of BDNF to be conﬁned to myoﬁbers in adult
rat muscle [34] and that other cells in normal muscle do
not contribute to BDNF expression. However, Mousavi and
Jasmin [35] demonstrated more recently the expression of
BDNF in normal satellite cells of several muscles in adult
mice. Using three diﬀerent methods (reverse transcription-
PCR, in situ hybridization, and immunoﬂuorescence), they
found the clear colocalization of both BDNF and the
receptor p75NTR with Pax3, a marker of satellite cells, in
the diaphragm, soleus, and EDL muscle of mature mice.
Furthermore, they showed that BDNF was not expressed
at signiﬁcant levels within mature myoﬁbers and did not
accumulate within subsynaptic regions of neuromuscular
junctions. Consistent with these observations, Liem et al.
[34] reported that subsynaptic regions of NMJs in soleus
muscle were devoid of BDNF transcripts. The expression
of BDNF in NMJs has been controversial. It has been
hypothesized that skeletal-muscle-derived BDNF enhances
the survival of innervating motor neurons throughout
their lifespan and potentiates neuromuscular transmission
[36, 37]. This hypothesis is supported by several lines of
evidence including, for example, the expression of BDNF
in skeletal muscle and retrograde transport of exogenously
applied BDNF to distinct motor neuron cell bodies [3, 38,
39]. As postulated by Mousavi and Jasmin [35], mature
NMJs unlike the central nervous system (CNS) may be
stable arrangements that do not require BDNF signaling for
remodelingandmodulationofneuromusculartransmission.
NT-4/5 expression is dependent on the activity of
neuromuscular synapses. Electrical stimulation of motor
nerves enhanced NT-4/5 expression in skeletal muscle, and
a blockade of neuromuscular endplates with bungarotoxin
led to reduced NT-4/5 expression [39]. Although NT-4/5
expression appears relatively strong in skeletal muscle of
adult rats, several studies including our own suggest the
expression of NT-4/5 to be dependent on ﬁber type [14, 40].
One study found NT-4/5 to be equally distributed in both
muscle types in humans [40], while another, using in situ
hybridization and immunohistochemistry, found NT-4/5 to
be selectively expressed in the slow-twitch ﬁbers of mice.
In contrast, our Western blot analysis [14] demonstrated
that NT-4/5 expression is higher in fast-type (extensor
digitorum longus, tibialis anterior, and gastrocnemius) than
slow-type (soleus) muscles. Immunohistochemical analysis
revealed NT-4/5 protein within vesicle-like structures that
are diﬀusely distributed in the cytosol of muscle ﬁbers
in the tibialis anterior muscle. Low levels of NT-4/5
immunoreactivity were also observed around the edge of
soleus muscle ﬁbers. Furthermore, Carrasco and English [7]
found, using Fisher 344 rats, that intramuscular injections
of recombinant NT-4/5 (1.5μg) into the soleus muscle
of neonates signiﬁcantly accelerated the normal fast-to-
slow myosin heavy chain (MHC) isoform transformation.
The sequestration of endogeneous NT-4/5 with TrkB-IgG
prevented this transformation from occurring. Intriguingly,
administration of another TrkB ligand did not aﬀect the
normal course of the transformation in this muscle. In their
study, the developmental upregulation of NT-4/5 mRNA
expression in rat soleus muscle ﬁbers occurred earlier than
theupregulationofMHCImRNAexpressionassociatedwith
muscle ﬁber transformation. This ﬁnding would indicate
that the NT-4/5 protein is expressed more abundantly in
the soleus muscle because of the slow-type characteristics.
Although the expression pattern of NT-4/5 appears to diﬀer
depending on the species of animal and with postnatal
growth, NT-4/5 is important for maintaining various func-
tions (ﬁber-type conversion, survival of motoneuron, the
formation of NMJ, etc.) in skeletal muscle.
The expression of GDNF has been found in a variety of
tissuesandcellsoutsideoftheCNS,includingskeletalmuscle
and Schwann cells [21, 41, 42]. Earlier studies indicated
that GDNF is important to the survival of motoneurons
during myogenesis and regulates the postnatal change from
multi-innervation to single innervation. In general, GDNF
expression seems to peak during early myogenesis and to be
negligible in mature skeletal muscle. A more recent study
clearly demonstrated the existence of GDNF mRNA and
protein in both slow-type soleus and fast-type EDL muscles,
especially the former [43].
2.2. Neurotrophin Receptors. Figure 1 indicates possible
interactions between several neurotrophins and these recep-
tors in mammalian muscle. The low-aﬃnity NT receptorJournal of Biomedicine and Biotechnology 3
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Figure 1: The interaction (preference of binding) between neurotrophins and these receptors. The low-aﬃnity receptor p75NTR binds all
neurotrophins with similar aﬃnity but not diﬀerent kinetics. Trk receptors are a family of transmembrane glycoprotein, which includes
three members, TrkA, TrkB, and TrkC. The full-length TrkA, TrkB, and TrkC have estimated molecular weights of 140, 145, and 145kDa,
respectively. Each Trk preferentially binds a single neurotrophin. TrkA is the receptor for NGF, both BDNF and NT-4/5 bind to TrkB, and
NT-3istheligandforTrkC.GDNFdimerformsacomplexwithGFR-α1,andthiscomplexinducesdimerizationofRet.BDNF:brain-derived
neurotrophic factor, GDNF: glial cell-line derived neurotrophic factor, and NT-4/5: neurotrophin-4/5.
(p75NTR) binds both neurotrophin precursor proteins and
all mature neurotrophins. It is expressed in developing rat
myoblasts and in adult rat and chicken muscle [44–46].
In chicks, all somitic cells strongly express p75NTR mRNA
during early development [47]. Subsequently, as the somite
becomes subdivided into the dermatome, myotome, and
sclerotome, p75NTR mRNA expression becomes high in
dermatome and sclerotome and decreases to low levels in the
myotome [45].
In the adult rat, both the long form of TrkA mRNA
and a short isoform that lacks 18 base pairs coding for an
insert in the extracellular region are expressed in skeletal
muscle [45]. TrkB is also found in the muscle of adult
mice [48]. Our group found that the truncated TrkB was
highly expressed in muscle, but the full-length TrkB was also
detectable, at least at low levels [14, 45]. TrkB expression
varies depending on the type of skeletal muscle [14, 45].
TrkB is more abundant around the edge of myoﬁbers of
the soleus muscle than gastrocnemius muscle. Full-length
TrkB and TrkB-T1 appear in close proximity to motor
endplates in skeletal muscle. In contrast, a more recent
study [49] using real-time PCR detected both the truncated
and full-length TrkB mRNA in the predominantly fast-
twitch medial gastrocnemius muscles. It is possible that the
equivocal results regarding the expression of TrkB in skeletal
muscle are due to methodological diﬀerences, because there
are discrepant sensitivities between the sensitivity of tech-
niques utilized to establish protein versus mRNA expression
changes. Other studies have found the colocalization of TrkB
with mitochondrial membrane [50] and endothelial cells
[51] in skeletal muscle, although the role of TrkB at these
l o c a t i o n si sn o te n t i r e l yu n d e r s t o o d .
Both GDNF receptor (GFR)α1 and GFRα2 are expressed
abundantly in the developing and adult central and periph-
eral nervous systems [52, 53]. GFRα3m R N Aw a sd e t e c t e di n
spleen,lung,liver,heart,andkidney,butnotinbrain,skeletal
muscle, or testis [54].
2.3. Neurotrophins at NMJs. Whether and if so how neu-
rotrophins modulate the development and function of
motor endplates in skeletal muscle has still not been fully
elucidated.Neurotrophinshavebeenshowntopotentiatethe
spontaneous activity of developing neuromuscular synapses
in culture [55, 56]. The situation in vivo,h o w e v e r ,i sl e s s
clear. Overexpression of NT-4/5 in myoblasts in developing
Xenopus laevis embryos leads to the enhanced release of
acetylcholine in innervating motor terminals, and additional
postsynaptic eﬀects were observed with increased mean
burst duration of low-conductance acetylcholine (ACh)
receptor (AChR) channels [57]. NT-4/5 overexpression in
myocytes leads to the enhanced spontaneous activation of
skeletal muscle [57]. This suggests that NT-4/5 modulates
neuromuscular transmission and that this involves eﬀects via
pre- and postsynaptic TrkB receptors. Indeed, a more recent
study [58] using confocal microscopy clearly demonstrated
immunoreactivity to BDNF, NT-4/5, p75, and TrkB at NMJs
in the mouse levator auris longus muscle.
Both BDNF and NT-4/5 acted on TrkB receptors in the
pre- and postsynaptic part of the NMJ [59, 60]. BDNF and
NT-4/5 inhibited agrin-induced AChR clustering in cultured4 Journal of Biomedicine and Biotechnology
c h i c k e nm y o t u b e s ,w h e r e a sN G Fa n dN T - 3h a dn oe ﬀect
[60].
It was demonstrated that GDNF enhanced spontaneous
neurotransmitter release in amphibian neuron-myocyte
cocultures and isolated neuromuscular preparations from
mice [61]. Treating frog neuron-muscle co-cultures with
GDNF increased the frequency as well as amplitude of
spontaneous synaptic currents [62]. In addition, using quan-
titative data from double-labeled imaging, Yang and Nelson
[63] found that GDNF induced a quick and substantial
increase in AChR insertion as well as lateral movement into
AChR aggregatesinthesurfacemembraneofmouseprimary
cultured muscle cells. Furthermore, transgenic mice with
muscle-speciﬁc overexpression of GDNF exhibit hyperinner-
vationofthemuscleatbirthanddelayedsynapseelimination
[21]. Although all of the ﬁndings made in vitro and with
transgenic mice show that GDNF plays an important role
in the formation and maturation of NMJs, there is no direct
evidence (e.g., immunoﬂuorescence) that the GDNF protein
exists at NMJs in normal mammalian skeletal muscle in vivo.
3. Effect of Exercise on Neurotrophin and
Neurotrophin Receptor Expression
Increased physical activity has been shown to alter the
structureandfunctionoftheNMJ.Exercise increasesthesize
anddegreeofbranchingofmotornerveterminalsattheNMJ
[64], the total area of both pre- and postsynaptic elements
[65], and the amount of ACh released [66]. Endurance
exercise in young animals results in the hypertrophy of nerve
terminals and an increase in neurotransmitter release [67].
Increased exercise training has also been shown to have
eﬀects on neurotrophic factor expression in mammalian
skeletal muscle. BDNF mRNA expression has consistently
been shown to increase in the CNS and peripheral nervous
system(PNS)inadose-dependentmannerfollowingexercise
[68, 69]. Recently, brief treadmill training bouts over 5 days
were found to produce large increases in BDNF mRNA
in soleus muscle [70, 71] that do not follow the positive
dose-response relationship originally demonstrated in the
nervous system with voluntary wheel running [68, 69, 72,
73]. As BDNF and NT-4/5 can initiate intracellular signaling
through the same cell surface receptor, TrkB [74, 75], it is of
interest that NT-4/5 has not been evaluated following similar
exercise. To date, only one study has addressed the issue of
exercise-induced NT-4/5 expression, ﬁnding no signiﬁcant
elevation of NT-4/5 protein levels in the vastus lateralis of
two aerobically trained individuals.
InSprague-Dawleyratsexercisedonatreadmillatspeeds
of up to 20m/min with a 5% incline, BDNF mRNA expres-
sion was enhanced in soleus muscle following 5 days (184%)
but not 10 days of exercise. NT-4/5 and TrkB mRNA levels
were not aﬀected at either time point. The exercise-elicited
increase in BDNF expression in muscle seems to inﬂuence
neurotrophin levels in motoneurons. G´ omez-Pinilla et al.
[69] indicated a marked increase in BDNF mRNA but not
p r o t e i ni ns o l e u sm u s c l ea f t e r5c o n s e c u t i v ed a y so ft r e a d m i l l
training. In contrast, ELISA and immunohistochemistry
showed an increase in the protein but not mRNA in
lumbar motoneurons after this training. It is known that
motoneurons can retrogradely transport BDNF that has
been injected into skeletal muscle [76] or the sciatic nerve
[77, 78] and that the administration of BDNF can prevent
the degeneration of motoneurons [76, 78]. These ﬁndings
raise the question of whether these neurotrophic factors
play a role in the routine maintenance and plasticity of the
neuromuscular system.
Wehrwein et al. [43] showed that GDNF protein content
increased with involuntary exercise in skeletal muscle but
decreased with hindlimb suspension. This adaptation of
GDNF protein content elicited by exercise seems to be
dependent on muscle ﬁber type. More recently, McCullough
et al. [79] found that low-intensity exercise (10m/min,
45min/day, 2 weeks) increased and decreased the amount
of GDNF in the soleus and EDL muscles, respectively, corre-
sponding with the change in the average endplate area. Such
a change in GDNF content was observed after both 4 hours
of electrical stimulation and mechanical stretching in both
muscles. Interestingly, pretreatment with α-bungarotoxin
blocked the stretch-induced decrease in GDNF protein in
EDL muscle and uncovered a stretch-induced increase in the
pr oteininsoleusmuscle.Ther efor e,A Chma yactonnA ChRs
to regulate GDNF protein content. The application of GDNF
increased spontaneous transmitter release from motor nerve
terminals in skeletal muscles of both neonatal mice [61]
and from nerve muscle co-cultures [62]. Treatment with
exogeneous GDNF caused continuous synaptic remodeling
and axonal branching at the NMJ [80]. Figure 2 provides an
overview of molecular pathway of neurotrophic factors to
regulate to neurotransmission, hypertrophy, or fat oxidation
in skeletal muscle.
4. Possible Role of Neurotrophins during
Muscle Regeneration
Experimental results indicate neurotrophins (particularly
NGF) to be involved in muscle regeneration. NGF improved
the muscle-regenerating capacity of muscle stem cells in
dystrophic muscle [81]. In addition, phenotypic knockout
of NGF resulted in skeletal muscle atrophy and dystrophy
in adult mice [6, 82]. In humans, regenerating muscle ﬁbers
from patients aﬀected by Duchenne and Becker muscular
dystrophies consistently express NGF, as do myoﬁbroblasts
and mast cells. Interestingly rest ﬁbers from healthy subjects
did not show NGF immunoreactivity or NGF protein [6].
Moreover, regenerating myoﬁbers expressed NGF recep-
tors, TrkA-receptor [83]a sw e l la sp 7 5 NTR [84]. Taken
together, these results indicate that, in dystrophic muscles,
NGF expression might be able to trigger and favor the
regeneration process. In fact, Deponti et al. [85]p r o v i d e d
the direct evidence that NGF-p75NTR signaling regulates
the diﬀerentiation of satellite cells in vivo. They utilized
a tissue-permeable form of a NGF-competing peptide
(P75NTRTAT4) or the control peptide TAT4 starting 48h
after damage (cardiotoxin injection). Six days after the
cardiotoxin injection, regenerating centro-nucleated ﬁbersJournal of Biomedicine and Biotechnology 5
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Figure 2: Schematic diagram of the functional role of skeletal muscle-derived neurotrophic factors after exercise. Exercise (neuromuscular
activity) increases BDNF expression in skeletal muscle. In the patients with spinal cord injury, BDNF stimulates protein synthesis by
activatingAkt/mTOR/p70S6KpathwaythroughTrkBreceptoronmusclemembrane.BDNFalsopromotesthefatoxidationthroughAMPK-
ACCsignaling.BDNFproducedbyskeletalmuscleafterexercisemaycirculateintobraintoimprovetheimpairedlearningand/ordepression.
Increased GDNF protein after exercise promotes the amount of neurotransmitter (e.g., ACh) at NMJ by conjugating with Ret in presynaptic
region (axon terminal). NT-4/5 may possess similar role of GDNF. BDNF: brain-derived neurotrophic factor, GDNF: glial cell-line derived
neurotrophic factor, NT-4/5: neurotrophin-4/5, NMJ: neuromuscular junction, TORC1: a component of TOR signaling complex 1, Rheb:
Ras homolog enriched in brain, mTOR: mammalian target of rapamycin, AMPK: AMP-activated protein kinase, and ACC: acetyl CoA
carboxylase.
were present in the control, whereas no regeneration was
apparent in the muscles treated with P75NTRTAT4. At 10
days, regeneration occurred also in the P75NTRTAT4-treated
animals, however, it was signiﬁcantly less extensive than
in controls with a persistence of embryonic MHC. At this
time, they observed the marked upregulation in RhoA-GTP
expression in regenerating muscle treated with P75NTRTAT4
compared to control muscle. During muscle regeneration
in vivo,N G F - p 7 5 NTR signaling seems to promote myogenic
diﬀerentiation by inhibiting RhoA-GTP as demonstrated in
vitro using pull-down assays [85].
The role of BDNF in skeletal muscle development and
function has been diﬃcult to determine due in part to
the early postnatal death of the BDNF knockout mouse
(BDNF−/−)[86]. More recently, Clow and Jasmin [87]
generated a mouse in which BDNF is speciﬁcally depleted
from skeletal muscle cells to examine the functional role
of muscle-derived BDNF in vivo. Mice carrying the LoxP-
targeted BDNF allele (BDNFf/f) were crossed with Myf5-
Cre mice to generate BDNFf/wt;Myf5-Cre progeny, and
then backcrossed with BDNFf/f homozygotes to produce
BDNFf/f; M y f 5 - C r em i c e( B D N F MKO). At P7, BDNF tran-
script levels were decreased by ∼50% in BDNFMKO muscles
compared with controls. Although overall muscle histology
is not aﬀected in the absence of muscle-BDNF, they observed
the decreased expression (by 30%) of a satellite cell marker,
Pax7. After the injection with cardiotoxin, BDNF-depleted
muscle showed lower levels of diﬀerentiation-promoting
factors such as myogenin, MyoD, and embryonic MHC as
well as the delayed appearance of newly centrally nucleated
ﬁbers in the regenerating muscle during 1–5 days [87].
Furthermore, treatment with exogeneous BDNF protein was6 Journal of Biomedicine and Biotechnology
suﬃc i e n tt or e s c u en o rm a lg e n ee x p r e s s i o na n dm y o t u bes i z e
in BDNFMKO mice probably due to the upregulation of Pax7
expression.
In contrast, a previous study by this same group showed
that siRNA-mediated depletion of BDNF resulted in the
precocious diﬀerentiation of rat L6 myoblasts [35]. There
are many possible causes for the disparity observed between
these studies. First, there are intrinsic diﬀerences in the
properties of immortalized cell lines and primary cultures.
Second, the developmental timing of BDNF depletion dif-
fered between these studies. These diﬀerences, in conjunc-
tion with the diﬀerent mechanisms used to deplete BDNF
expression (siRNA transfection versus transgenic knock-
out) could result in altered responses of satellite cells to
signals that promote growth, diﬀerentiation, or both. Finally,
it becomes important to consider that many features of
embryonic muscle development are recapitulated during
muscle regeneration, with similar changes in muscle gene
expression, physiological properties, and functional charac-
teristics. In BDNFMKO muscle, Pax7 expression is decreased,
satellite cell diﬀerentiation is defective, and regeneration is
delayed.
GDNF signaling seems to have an important role during
muscle regeneration. Using in situ hybridization histochem-
istry, Kami et al. [88] investigated whether the expression of
GDNF-linked molecules signiﬁcantly changes in regenerat-
ing muscle. They utilized muscle contusion to elicit extensive
damage,becausethisapproachdirectlydamagesmusclecells,
blood vessels, intramuscular nerves, and extracellular matrix
components. They found that muscle contusion induced
increases in GDNF and GFRα1m R N A si nS c h w a n nc e l l -
like cells in the intramuscular nerves. GFRα1a n dR E T
mRNAexpressioninmotoneuronswasupregulated.Wehave
also observed such motoneuronal activation after muscle
damage with bupivacaine [14]. Our immunoprecipitational
analysis clearly showed the phosphorylation of TrkB in the
spinal cord at 1 day after pharmacological muscle damage
(bupivacaine). These ﬁndings suggest that a rapid and
prominent increase in the receptor components for GDNF
or TrkB in motoneurons is important for the regeneration of
intramuscular motor nerves damaged by muscle contusion
and bupivacaine injections.
5. Neurotrophin andNeuromuscular Disorders
5.1. Sarcopenia. Aging is associated with a progressive
decline of muscle mass, quality, and strength, a condition
known as sarcopenia [89] .A g e - r e l a t e dm u s c l el o s si sa
result of reductions in the size and number of muscle ﬁbers
possibly due to a multifactoral process that involves physical
activity, nutritional intake, oxidative stress, and hormonal
changes [90, 91]. The speciﬁc contribution of each of these
factors is unknown but there is emerging evidence that
the disruption of several positive regulators (Akt and SRF
(serum response factor)) of muscle hypertrophy with age
is an important feature in the progression of sarcopenia
[92–94]. In addition, marked motoneuron loss and aber-
rant neuromuscular sprouting have been observed in aged
mammals. Neurotrophic factors expressed in skeletal muscle
are essential to motoneuron survival and muscle ﬁber inner-
vation during development. Spinal motoneurons express
cognate receptors for these neurotrophic factors, and during
aging, major changes take place in their expression pattern.
Whereas the expression of TrkB and Trk C is downregulated,
that of the components of the GDNF receptor (GFRα1a n d
Ret) is upregulated [95]. This pattern of regulation mirrors
the altered expression of the corresponding neurotrophic
factors in target muscles [22]. GDNF, one of the most
potent neurotrophic factors for motoneurons, is markedly
up-regulated in human as well as rat muscle tissue during
aging [22]. In addition, muscle-derived CNTF receptor-α
is considered to play an important role in muscle ﬁber
innervation/reinnervation [96]. Edstr¨ om et al. [97] showed
increased levels of CNTF receptor-α in sarcopenic muscle
compared with normal adult muscle. The increase in GDNF
andCNTFreceptor-αinsarcopenicmusclesprobablyreﬂects
signaling from regenerating/denervated muscle ﬁbers to
attract motor axons. Although this is evidence for increased
GDNF signaling from muscle to motoneurons during aging,
it is not suﬃcient to restore appropriate innervation of the
muscle ﬁbers.
5.2. Myopathies. As in animal models, pathological situa-
tions can modify neurotrophin expression. NGF concentra-
tions were measured by enzyme immunoassay in muscle
biopsies from subjects with amyotrophic lateral sclerosis
(ALS) or inﬂammatory myopathies [13]. NGF levels were
signiﬁcantly (140%) higher in patients with ALS than in the
control subjects. In inﬂammatory myopathies, the increase
was not signiﬁcant. Age and gender had no inﬂuence on
NGF concentrations in muscle. However, both mRNA and
protein levels of NGF, BDNF, and NT-4/5 were increased in
postmortembiopsiestissueof15ALSpatientsincomparison
to controls, suggesting that some of the earlier data have to
be reinvestigated and only biopsies from individuals with a
postmortem period of less than 3h should be tested [98].
During the course of the disease, upregulation of BDNF
expression is observed in the early phase and the increase of
NGF and NT-4/5, in later stages. In the spinal cord of ALS
patients, a reduction in BDNF and no signiﬁcant change in
the amount of NT-4/5 were observed in spite of the elevated
NGF expression. A decreased level of phosphorylated TrkB
proteinwasalsodetected,suggestingimpairedTrkBsignaling
[99]. Importantly, p75NTR expression was induced in spinal
cord motoneurons and denervated Schwann cells in ALS
[100, 101]. Collectively, these results suggest that motor
neurons switch from BDNF to NGF responsiveness in
human ALS. Systemic administration of a modiﬁed cyclic
decapeptide p75NTR antagonist conjugated to the TAT4 cell
permeabilization sequence to presymptomatic transgenic
SOD1G93A mice aﬀected neither disease onset nor disease
progression, as determined by hindlimb locomotion, grip
strength, and survival [102].
In muscle from patients with DMD, NGF was expressed
in regenerating ﬁbers and connective tissue myoﬁbroblast
[103]. Rest ﬁbers from dystrophic patients, as well as muscle
ﬁbers from healthy subjects and regenerative muscle ﬁbers
in patients with polymyositis (PM), did not show NGFJournal of Biomedicine and Biotechnology 7
immunoreactivity. In another study, NT-4/5 protein and
mRNA were found in both type I and type II ﬁbers of healthy
aerobically trained athletes and patients with mitochondrial
encephalomyopathies [40]. However, in ragged-red ﬁbers,
which are present more frequently in highly oxidative type
I ﬁbers than in glycolytic type II ﬁbers of patients with
mitochondrial encephalomyopathies, NT-4/5 expression is
upregulated in contrast to muscle ﬁbers from healthy
subjects.
P75NTR expression has also been found in normal and
pathological human muscle [84, 104]. Normal muscle cells
from 12- to 22-week-old fetuses stained strongly for P75NTR
[84]. In adult muscle, only intramuscular nerve endings
showed immunoreactivity with no staining detected in
muscle ﬁbers [84]. The outer surface of some regenerating
muscleﬁbers, in muscle biopsy specimens from patients with
muscular dystrophies, was positively stained for P75NTR [84,
104]. P75NTR mRNA expression was also detected using in
situ hybridization in such cells.
Some muscular dystrophies would aﬀect the amount of
neurotrophin in the CNS as well as skeletal muscle. Our
previous study [105] indicated the upregulation of GDNF
protein and reciprocal downregulation of NT-4/5 protein
in cerebellum and spinal cord motoneurons of merosin-
deﬁcient dy mice. In particular, our immunohistochem-
ical analysis using dy mice clearly showed the marked
enhancement of GDNF protein in the Purkinje and granule
cells of the cerebellum and in many lumbar motoneurons.
At this time, the microtubule-associated protein-2 (MAP-
2) protein level was markedly decreased in these regions.
Therefore, GDNF expression in the cerebellum and spinal
cord appears to play a role in the fundamental disorders
caused by a lack of merosin. Nico et al. [106]f o u n d
marked immunoreactivity of NGF in neurons, astrocytes,
and ependymal cells in the mdx brain diﬀerent to the faint
NGF expression only in neurons and astrocytes. In addition,
they demonstrated that mdx brain possessed NGFRs on both
glial and endothelial cells diﬀerent to the absence of NGFR
proteinexpressioninendothelialcellsincontrols.Sincesome
muscular dystrophies include a disorder of the CNS, elevated
and/or decreased neurotrophin levels may further degrade
the pathological symptoms.
5.3. Spinal Cord Injury. Spinal cord injury is a devastat-
ing neurological condition that produces muscular pare-
ses/paralyses caudal to the lesion level, leading to a pro-
nounced loss of muscle mass and severe muscle atrophy
[107]. This paraplegia-induced muscle atrophy increases
the risk of developing secondary health problems such as
cardiovascular disease and diabetes in paraplegic patients
[108]. Muscular disuse severely reduces the expression of
BDNF protein and mRNA in both lumbar spinal cord and
soleus muscle in acute and chronic stages after spinal cord
injury. This trophic factor can activate rapamycin (mTOR),
a protein that participates in mammalian cell size control
and plays an important role in muscular tropism [109].
Furthermore, paraplegia-induced muscle atrophy in rats
has been associated with a downregulation of the mTOR
signaling pathway [110].
Studies have shown that repetitive motor activity, such as
cycling exercise training, accelerates muscle size restoration
after complete spinal cord injury in rats [111, 112]. In
addition, treadmill training has been shown to diminish
the extent of muscle atrophy [107]a n dr e s t o r e sB D N F
levels in both the lumbar spinal cord and soleus muscle
[113] in moderate spinal cord injury models. Furthermore,
more recently, Ilha et al. [114] conducted a 9-week step-
program for rats with complete spinal cord transection
(SCT) at T8-T9. Step training, initiated immediately after
SCT in rats, partially reverted muscular atrophy in chronic
paralyzed soleus muscle possibly due to BDNF upregula-
tion. Therefore, BDNF produced in response to treadmill
training appears to ameliorate the symptoms of spinal cord
injuries.
5.4. Diabetes. BDNF has been identiﬁed as a key component
of the hypothalamic pathway that controls body weight and
energy homeostasis [115]. Most recently, Pederson et al. have
shown that BDNF appears to be a major player not only
in central metabolic pathways but also as a regulator of
metabolism in skeletal muscle [13]. Interestingly, individuals
with both obesity and type 2 diabetes possess low levels of
circulating BDNF [116] similar to patients with Alzheimer’s
disease [117], major depression [118], or acute coronary
syndrome [119]. In a human in vivo model, Pedersen et
al. [120] demonstrated that the cerebral output of BDNF
was inhibited under hyperglycemic clamp conditions. The
latter ﬁnding may explain the concomitant ﬁnding of low
circulatinglevelsofBDNFin individualswithtype2diabetes
and the association between low plasma BDNF levels and
the severity of insulin resistance [116]. The human data are
in accordance with reports from animal models suggesting
that BDNF also plays a role in insulin resistance and in
energy balance. BDNF administration has beneﬁcial eﬀects
on glucose homeostasis and improves insulin resistance in
obese diabetic animal models, such as C57BL/KsJ-db/db
mice, even when food intake is controlled [121, 122]. It
was found that BDNF mRNA and protein expression were
increased in human skeletal muscle after exercise; however,
muscle-derived BDNF appeared not to be released into
the circulation. Since BDNF increased the phosphorylation
of AMP-activated protein kinase (AMPK) and acetyl CoA
carboxylase and enhanced fat oxidation both in vitro and
ex vivo, contraction-induced muscle-derived BDNF may
increase fat oxidation in an AMPK-dependent fashion.
6. Conclusions
This paper summarized and highlighted the current under-
standing of the normal distribution and functional role of
neurotrophin in skeletal muscle during exercise, regener-
ation, and disorders. In particular, many researchers are
interested in the important role of BDNF in learning and
memory [123] or glucose metabolism as well as adaptations
in skeletal muscle. A strategy for controlling the amount of
BDNFmaybealsoeﬀectiveinthefuturetreatmentofvarious
muscular disorders.8 Journal of Biomedicine and Biotechnology
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